UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Olaparib for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-05, Vol.382 (22), p.2091-2102

2020

Link zum Volltext

Verfügbarkeit prüfen

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2015-08, Vol.373 (8), p.737-746

2015

Link zum Volltext

Verfügbarkeit prüfen

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-06, Vol.382 (23), p.2197-2206

2020

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

The New England journal of medicine, 2004-10, Vol.351 (15), p.1513-1520

2004

Link zum Volltext

Verfügbarkeit prüfen

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)

The Journal of urology, 2012-10, Vol.188 (4), p.1164

2012

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Link zum Volltext

Verfügbarkeit prüfen

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)

Journal of clinical oncology, 2022-10, Vol.40 (28), p.3301-3309

2022

Link zum Volltext

Verfügbarkeit prüfen

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1080-1087

2018

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory Bowel Disease and the Risk of Prostate Cancer

European urology, 2019-05, Vol.75 (5), p.846-852

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2005-05, Vol.23 (15), p.3562-3567

2005

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

Journal of clinical oncology, 2011-05, Vol.29 (15), p.2040-2045

2011

Link zum Volltext

Verfügbarkeit prüfen

Identification of targetable FGFR gene fusions in diverse cancers

Cancer discovery, 2013-06, Vol.3 (6), p.636-647

2013

Link zum Volltext

Verfügbarkeit prüfen

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

Clinical cancer research, 2018-09, Vol.24 (17), p.4201-4214

2018

Link zum Volltext

Verfügbarkeit prüfen

Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions

Prostate cancer and prostatic diseases, 2021-06, Vol.24 (2), p.558-566

2021

Link zum Volltext

Verfügbarkeit prüfen

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Journal of clinical oncology, 2016-04, Vol.34 (12), p.1402-1418

2016

Link zum Volltext

Verfügbarkeit prüfen

Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy

Current treatment options in oncology, 2024-03, Vol.25 (3), p.293-312

2024

Link zum Volltext

Verfügbarkeit prüfen

Antiandrogen Withdrawal in Castrate-refractory Prostate Cancer : A Southwest Oncology Group Trial (SWOG 9426)

Cancer, 2008-06, Vol.112 (11), p.2393-2400

2008

Link zum Volltext

Verfügbarkeit prüfen

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clinical cancer research, 2021-04, Vol.27 (7), p.1967-1973

2021

Link zum Volltext

Verfügbarkeit prüfen

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

The New England journal of medicine, 2013-04, Vol.368 (14), p.1314-1325

2013

Link zum Volltext

Verfügbarkeit prüfen

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details

Journal of clinical oncology, 2016-01, Vol.34 (3), p.280-285

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

Clinical cancer research, 2010-06, Vol.16 (11), p.3028-3034

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

Journal of clinical oncology, 2018-04, Vol.36 (10), p.991-999

2018

Link zum Volltext

Verfügbarkeit prüfen

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies

Cancer, 2017-06, Vol.123 (11), p.1912-1924

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 599

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(573)
Mit Volltextzugriff
(550)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(359)
Life Sciences & Biomedicine
(327)
Humans
(278)
Male
(245)
Oncology
(192)
Aged
(127)
Middle Aged
(124)
Prostate Cancer
(95)
Prostatic Neoplasms - Drug Therapy
(95)
Biological And Medical Sciences
(92)
Prostatic Neoplasms - Pathology
(92)
Medical Sciences
(89)
Urology & Nephrology
(75)
Aged, 80 And Over
(72)
Tumors
(70)
Treatment Outcome
(66)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(60)
Female
(59)
Adult
(56)
Nephrology. Urinary Tract Diseases
(55)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(162)
Cancer
(32)
The Journal Of Urology
(20)
Clinical Cancer Research
(16)
The New England Journal Of Medicine
(16)
Urology
(16)
Cancer Research
(12)
European Urology
(12)
Clinical Genitourinary Cancer
(10)
Investigational New Drugs
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Inflammatory Bowel Disease and the Risk of Prostate Cancer

Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

Identification of targetable FGFR gene fusions in diverse cancers

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy

Antiandrogen Withdrawal in Castrate-refractory Prostate Cancer : A Southwest Oncology Group Trial (SWOG 9426)

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies

Suchergebnisse filtern